VANCOUVER, BRITISH COLUMBIA--(Marketwire - March 04, 2009) - Perceptronix will be exhibiting at the Pacific Dental Conference on March 5 - 6, 2009 at the Vancouver Convention and Exhibition Centre. Perceptronix will be showcasing OralAdvance™, an innovative quantitative cytology test for the early detection of oral cancer, and demonstrating its use at booth 316.
With recent advances in visualization techniques for the oral cavity, dentists are encountering more suspicious lesions. OralAdvance™, with its soft cyto-brush sample collection kit, provides dentists with an informative new option for assessing these lesions when biopsy is not warranted or possible. It provides an objective measure of gross DNA abnormality that can give additional information about the pre-malignant or malignant nature of a lesion.
About Perceptronix Medical Inc.
Perceptronix Medical Inc. (Vancouver, Canada) is a private laboratory and cancer diagnostics company specializing in the provision of innovative early cancer detection tests based on quantitative cytology. The Company's DNA image cytometry technology was developed in partnership with the British Columbia Cancer Agency (Vancouver, Canada). Quantitative cytology provides physicians with an innovative cytopathology assessment based on an objective measure of large-scale DNA abnormality that can indicate precancerous or cancerous changes. The company has developed proprietary tests for the early detection of lung cancer and oral cancer using its DNA cytometry technology and offers quantitative cytology analysis of various tissues. For more information please visit our corporate website at www.perceptronix.com or the OralAdvance™ website at www.oraladvance.com.